Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
Aimmune Therapeutics, Inc. (AIMT)
Sector: Healthcare; Industry: Biotechnology

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2018-02-22 Tammenoms Bakker Juliet 10%-Owner Buy 9,375 $32.00 $300,000 No

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.

Insider Smart

Planet Fitness, Inc (PLNT) - Our position in PLNT is also inspired by insider trading, if insiders are comfortable and confident buying around $50, it is an easy hold if you can pick it up at an even lower price. Our avg cost of the position is ~$40 and is now with 50% profit.